Muhammad Ajmal Panezai, MD
Internal Medicine · Oklahoma City, OKNPI 1982954442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Vifor Pharma, Inc. at 32.7% of the total. Reporting peaked in 2019 at $284 and has fallen 79.8% since, to $58 in 2025.
Across 23 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$161
- AstraZeneca$80
- Veloxis Pharmaceuticals, Inc.$52
- Mallinckrodt Enterprises LLC$44
- Eurofins Viracor, LLC$37
- Apellis Pharmaceuticals, Inc.$32
- plus $86 from 5 others
What the payments were for
- Food & beverage$492100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 7 | $161 |
| AstraZeneca(2 entities) | 5 | $80 |
| Veloxis Pharmaceuticals, Inc. | 2 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $44 |
| Eurofins Viracor, LLC | 1 | $37 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| Bayer | 1 | $24 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
How this compares
$492 in reported general payments places this provider in the 60th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carvedilol | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.